摘要
目的考察白头翁皂苷B_(4)对咪喹莫特诱导的银屑病模型小鼠的炎症及免疫相关指标的影响,探讨其对小鼠银屑病的治疗作用及其机制。方法将56只BALB/c小鼠随机分成对照组,模型组,阿维A胶囊组(6 mg/kg),白头翁皂苷B_(4)低、中、高剂量(5、10、20 mg/kg)组,白头翁皂苷B_(4)乳膏组(20 mg/kg),每组各8只。通过局部涂抹5%咪喹莫特乳膏诱导小鼠银屑病模型,各组小鼠口服或涂抹相应药物,14 d后通过银屑病皮损面积及严重程度评分(PASI)评价小鼠皮损程度;HE染色观察皮肤组织病理学形态;血常规检测血液中免疫细胞的变化;酶联免疫吸附试剂(ELISA)检测小鼠皮肤中白细胞介素(IL)-6、IL-12、IL-17、IL-1β的水平。结果与模型组相比,阿维A胶囊组,白头翁皂苷B_(4)5、10、20 mg/kg组,白头翁皂苷B_(4)乳膏组小鼠皮损组织棘层厚度减小,真皮层炎症细胞浸润减少,PASI评分、血液中的免疫细胞及皮肤组织中IL-6、IL-12、IL-17、IL-1β的表达水平均显著降低。结论白头翁皂苷B_(4)对5%咪喹莫特诱导小鼠银屑病皮损具有明显的治疗作用,其机制可能是通过抑制IL-6、IL-12、IL-17、IL-1β等细胞因子表达发挥治疗作用。
Objective To investigate the effects of anemoside B_(4)on inflammation and immune-related indexes in imiquimote-induced mouse psoriasis model mice,and to explore its therapeutic effect and mechanism.Methods A total of 56 BALB/c mice were randomly divided into control group,model group,Avirin Capsule group(6 mg/kg),anemoside B_(4)low-dose,medium-dose and high-dose groups(5,10,20 mg/kg),Anemoside B_(4)Cream group(20 mg/kg),with 8 mice in each group.The psoriasis model of mice was induced by topical application of 5%imiquimod cream,and the psoriasis degree of mice was evaluated by psoriasis area and severity score(PASI)14 days later.The histopathological morphology of skin was observed by HE staining.Blood routine tests to detect changes in immune cells in the blood.The levels of IL-6,IL-12,IL-17,and IL-1βin mice skin were determined by enzyme-linked immunosorbent assay(ELISA).Results Compared with model group,the thickness of spinous layer of skin lesion tissue of mice in avitra capsule group,anemoside B_(4)5,10,20 mg/kg groups and Anemoside B_(4)Cream group decreased,and inflammatory cell infiltration in dermis decreased.PASI score,the expression levels of IL-6,IL-12,IL-17,and IL-1βin blood immune cells and skin tissue were significantly decreased.Conclusion Anemoside B_(4)has obvious therapeutic effect on 5%imiquimod-induced psoriasis in mice,and its therapeutic mechanisms may be through by inhibiting the expression of cytokines such as IL-6,IL-12,IL-17,IL-1βand other cytokines.
作者
李佶朗
苑仁祎坤
王琴琴
奉建芳
高红伟
杨世林
LI Ji-lang;YUAN Ren-yikun;WANG Qin-qin;FENG Jian-fang;GAO Hong-wei;YANG Shi-lin(College of Pharmacy,Guangxi University of Chinese Medicine,Nanning 530020,China;Guangxi Engneering Technology Research Center for Choice Chinese Patent Drug and Ethnic Drug Development,Nanning 530020,China)
出处
《现代药物与临床》
CAS
2022年第6期1169-1174,共6页
Drugs & Clinic
基金
广西创新驱动发展项目(桂科AA19254024)
广西科技计划项目(桂科AB20025002)。
